Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 14,161 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Endotracheal Extubation, Airway Obstruction, Airway Control, Pneumonia, Ventilator-Associated, Breathing Mechanics
Interventions: ETT cleaning maneuver; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acromegaly
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • New York, New York

Conditions: Dry Eye Disease
Interventions: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more

Conditions: Parkinson's Disease
Interventions: Istradefylline (KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Myotonic Dystrophy Type 1
Interventions: IONIS-DMPKRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Stanford, California • Gainesville, Florida • Kansas City, Kansas + 5 more

Conditions: Osteoarthritis, Knee
Interventions: JointStem, Synvisc-One; Drug
Lead sponsor: Nature Cell Co. Ltd.; Industry
Eligibility: 22 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Santa Monica, California • Walnut Creek, California

Conditions: Parkinson Disease
Interventions: Tavapadon, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 54
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more

Conditions: Healthy
Interventions: IW-1701, Placebo; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Crohn's Disease
Interventions: Placebo, ABT-874; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 36
States / cities: Orange, California • San Diego, California • Hamden, Connecticut + 30 more

Conditions: Healthy
Interventions: N6022, Placebo; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 134
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more

Conditions: Obesity
Interventions: Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo; Drug
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 70
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV LID cp ΔM2-2 Vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Prostate Cancer
Interventions: Remote Supervised Exercise Program; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 55 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Rosacea
Interventions: Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Osteogenesis Imperfecta
Interventions: AGA2115, Placebo; Drug
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Severe Asthma
Interventions: GB-0895, Placebo; Drug
Lead sponsor: Generate Biomedicines; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Northridge, California • Pasadena, California • Rancho Cucamonga, California + 32 more

Conditions: Hypercholesterolemia
Interventions: PRO-040201, Placebo; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obesity
Interventions: LLF580, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Jacksonville, Florida • Miami, Florida • Overland Park, Kansas + 4 more

Conditions: Healthy Volunteer, Cystic Fibrosis
Interventions: PTI-801, Placebo, PTI-808; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more

Conditions: Indolent Systemic Mastocytosis
Interventions: Masitinib, Placebo, Best Supportive Care; Drug · Other
Lead sponsor: AB Science; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Sacramento, California • Houston, Texas

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more

Conditions: Healthy
Interventions: Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

Efficacy Study of a Novel Device to Clean the Endotracheal Tube

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

Safety and Tolerability Study of N6022 in Healthy Subjects

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

RE-FIT (Remote Exercise for Physical Function in WTC Responders With Prostate Cancer)

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Safety Study of LLF580 in Obese Volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Multiple-Ascending Dose in Japanese Patients Bridging Study